Cancer Progress 2014 Presentations

• Jeff Bockman, PhD, VP, Defined Health

• Axel Hoos, MD, PhD, VP, Oncology Research and Development, GlaxoSmithKline

• Axel Hoos, MD, PhD, VP, Oncology Research and Development, GlaxoSmithKline

Panelists:

• Jeff Bockman, PhD, VP, Defined Health
• Ira Mellman, PhD, VP, Research Oncology, Genentech
• Galit Rotman, PhD, Chief Scientist of Therapeutics, Compugen
• Michel Sadelain, MD, PhD, Director, Center for Cell Engineering, Memorial Sloan Kettering Cancer Center
• Lauren V. Wood, MD, Senior Clinical Investigator, Vaccine Branch, National Cancer Institute

• Minesh P. Mehta, MD, Medical Director, Maryland Proton Treatment Center, University of Maryland

Panelists:

• Lauren Abrey, MD, Oncology Development Site Head, F. Hoffmann-La Roche Inc.
• Thomas Davis, MD, CMO and SVP Clinical Development, Celldex Therapeutics
• H. Ian Robins, MD, PhD, Faculty, University of Wisconsin School of Medicine and Public Health
• Eric Rowinsky, MD, Chief Medical Officer, Head of Research & Development, Stemline Therapeutics

• Colin Hill, Chief Executive Officer, President & Chairman, GNS Healthcare

Panelists:

• Alexis Borisy, Entrepreneur in Residence, Third Rock Ventures
• Joel Dudley, PhD, Director of Biomedical Informatics and Assistant Professor of Genetics and Genomics Sciences, Icahn School of Medicine at Mount Sinai
• Brian Leyland-Jones, MD, VP, Molecular and Experimental Medicine, Avera Health
• Michael Kolodziej, MD, National Medical Director, Oncology Solutions, Aetna
• Timothy J. Thompson, CEO, Intervention Insights

• Steven Averbuch, MD, VP, Translational Clinical Development & Pharmacodiagnostics, Bristol-Myers Squibb Company

Panelists:

• Anna Barker, PhD, Director, Transformative Healthcare Networks, Arizona State University
• Richard Brian Gaynor, MD, VP, Product Development/Medical Affairs, Eli Lilly and Company
• Steven Gutman, MD, Strategic Advisor, Myraqa
• Michael Kolodziej, MD, National Medical Director, Oncology Solutions, Aetna
• Howard I. Scher, MD, Chief, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center
• Kim Zerba, PhD, Group Director, Global Biometric Sciences, Bristol-Myers Squibb

• Steve Heller, Principal, OncStrat LLC

Panelists:

• Walter Capone, President, The Multiple Myeloma Research Foundation
• Jeanne Farrell, PhD, Business Development Director, Icahn School of Medicine at Mount Sinai • Debasish Roychowdhury, MD, President, Nirvan Consultants, LLC
• Mark J. Simon, Advisor, Torreya Partners LLC

• Jeremy P. Goldberg, President, JPG Healthcare LLC

Panelists:

• Richard Brian Gaynor, MD, VP, Product Development/Medical Affairs, Eli Lilly and Company
• Marco Gottardis, Ph D, VP and Prostate Cancer Disease Area Stronghold Leader, Oncology Therapeutic Area, Janssen Research & Development, LLC
• Richard Heyman, CEO, Seragon (ex-CEO Aragon)
• Philip Kantoff, MD, Director, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute
• Marianne Sadar, PhD, Distinguished Scientist, BC Cancer Agency. Professor of Pathology and Laboratory Medicine, University of British Columbia

• Mike Rice, MS, MBA, Senior Consultant, Defined Health

• Ed Saltzman, President, Defined Health

Panelists:

• Peter Bach, MD, Attending Physician, Memorial Sloan-Kettering Cancer Center
• Professor David Haslam, CBE, FRCGP, FRCP, FFPH Chairman, NICE
• Clifford A. Hudis, MD, Chief, Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, 2013-2014 President, ASCO

• Jeff Bockman, PhD, VP, Defined Health

Panelists:

• Robert Cohen, MD, Calico Life Sciences
• Jonathan Drachman, MD, SVP, Research and Translational Medicine, Seattle Genetics
• Hans-Peter Gerber, PhD, VP, BioConjugate Discovery & Development, Oncology Research, Pfizer
• John Lambert, PhD, EVP, Research & Development & Chief Scientific Officer, ImmunoGen, Inc.
• Peter Kiener, Ph D, Chief Scientific Officer, Ambrx, Inc.

• Mike Rice, MS, MBA, Senior Consultant, Defined Health

Panelists:

• Estuardo Aguilar-Cordova, PhD, Chief Executive Officer Advantagene, Inc.
• Renier J. Brentjens, MD, PhD, Director, Cellular Therapeutics, Memorial Sloan Kettering Cancer Center
• Nori Kasahara, M.D., Ph.D., Director, CURE Vector Core Facility JCCC Vector Shared Resources, Professor, Department of Medicine, Molecular & Medical Pharmacology, UCLA
• Angela Shen, MD, MBA, Global Clinical Program Head, CTL019, Oncology Clinical Development, Novartis Pharmaceuticals Corp

• Neal Rosen, MD, PhD, Director, Center for Mechanism-Based Therapeutics, Memorial Sloan Kettering Cancer Center

Panelists:

• Jeffrey A. Engelman, MD, PhD, Director of Thoracic Oncology and Director of Molecular Therapeutics, Massachusetts General Hospital Cancer Center
• Greg Plowman, MD, PhD, VP, Oncology Research Eli Lilly and Company
• David Solit, MD, Director, Developmental Therapeutics, Memorial Sloan Kettering Cancer Center

• Sol J. Barer, PhD, SJBarer Consulting LLC

Panelists:

• Rajesh Chopra, MD, PhD, Corporate VP, Translational and Early Drug Development, Celgene Corporation
• Giulio Draetta, MD, PhD, Director, Institute for Applied Cancer Science, Professor, Genomic Medicine, MD Anderson Cancer Center
• Tak Mak, PhD, University Professor, Ontario Cancer Institute, University of Toronto
• Neal Rosen, MD, PhD, Director, Center for Mechanism-Based Therapeutics, Memorial Sloan Kettering Cancer Center

• Jeffrey M. Bockman, PhD, VP, Defined Health
• Mike Rice, MS, MBA, Senior Consultant, Defined Health

Panelists:

• Joseph Beechem, PhD, SVP, Research and Development, NanoString Technologies
• Pamela Carroll, PhD, VP, Oncology, Innovation Center in Boston, Janssen Research & Development
• Rajesh Chopra, MD, PhD, Corporate VP, Translational and Early Drug Development, Celgene Corporation
• Victoria Richon, PhD, VP and Head of Cancer Research, Discovery and Early Development, Sanofi
• Spiro G. Rombotis, President & CEO, Cyclacel Pharmaceuticals, Inc.